David Sinclair plans to test whole-body rejuvenation drugs in the XPrize competition
Why this matters: a development in AI with implications for how people work, create, and decide.
The outspoken longevity scientist David Sinclair has been predicting that one day, you’ll go to the doctor and get a prescription that will make you 10 years younger. Now MIT Technology Review has learned that he has plans to launch human tests of an oral “reprogramming” drug as part of a $101 million competition organized by the XPrize Foundation. The foundation is offering cash awards to teams able to “restore” a person to an earlier apparent age, as measured by improvements in immune, cognitive, and muscle function. The grand prize goes to any team able to show a 10-year (or greater) relative improvement after one year of treatment. Reached by phone, Sinclair, a biologist at Harvard Medical School, confirmed that he plans to give an oral drug mixture to volunteers in a bid to seek “evidence for age restoration in humans.” The trial, if it goes forward, will be a significant new development in the race to harness so-called epigenetic reprogramming. That technology is based on the discovery, 20 years ago, of powerful genes able to turn an adult cell into a stem cell similar to those found in embryos. The age-reversal effect is believed to occur via a resetting of molecular controls on DNA known as epigenetic marks, which help determine a cell’s overall metabolism and identity. Companies are now racing to use that phenomenon for a new form of rejuvenation medicine. Only this January, one of Sinclair’s companies, Life Biosciences, made news by winning approval to launch an initial human trial using a set of powerful reprogramming genes. The company announced today it had treated its first patient. But that test involves a complex gene therapy and is limited to patients’ eyes, where it could treat conditions like glaucoma. Sinclair’s new plan is bolder: a reprogramming drug you’d swallow in order to promote such effects across the body. “What we’re aiming to do is to epigenetically restore the animal and eventually the person,” he says. “It is true that we